相关实验视频

Updated: Mar 7, 2026

Intramucosal Inoculation of Squamous Cell Carcinoma Cells in Mice for Tumor Immune Profiling and Treatment Response Assessment

Intramucosal Inoculation of Squamous Cell Carcinoma Cells in Mice for Tumor Immune Profiling and Treatment Response Assessment

Published on: April 22, 2019

马格罗利马布组合疗法在头部和部状细胞癌患者的II期研究

A D Colevas¹, V Chin², J J Park³

¹Stanford Cancer Center, Stanford, USA.

|March 5, 2026

概括

马格罗利马布组合治疗对转移性头角状细胞癌没有益处. 提升HNSCC研究提前结束,限制了关于马格罗利马布疗效的最终结论.

科学领域:

在瘤学瘤学.
免疫治疗是一种免疫疗法.
临床试验临床试验

背景情况:

第二阶段的ELEVATE HNSCC研究调查了对转移性头支状细胞癌 (mHNSCC) 的magrolimab组合.
患者之前未接受过治疗或接受过预治疗的复发/晚期mHNSCC.

研究的目的:

评估magrolimab与pembrolizumab结合的安全性和疗效以及未经治疗的mHNSCC中的化疗.
在预先治疗的mHNSCC患者中评估magrolimab加dcetaxel.

主要方法:

安全运行 (SRI),然后进行第二阶段评估.
没有接受治疗的队列:magrolimab,pembrolizumab和化疗 (MPemPF) 或pembrolizumab和化疗 (PemPF).
预先治疗的队列:马格罗利马布加多塞塔克塞尔 (MDtx). 主要终点:无进展生存率 (PFS) 和客观反应率 (ORR).

主要成果:

在SRIs中没有观察到剂量限制性毒性.
在未接受治疗的队列中,MPemPF (5.5个月) 和PemPF (5.6个月) 之间的PFS中位数相似.
在预治疗队列中,客观反应率 (ORR) 为12.2%. 在治疗手臂中发现了高水平的3-4级不良事件.

结论:

马格罗利马布治疗在本研究人群中没有显示出益处.
研究的过早结束限制了研究结果的解释性.

关键词:

多塞塔克塞尔 (Docetaxel) 是一种药物.马格罗利马布 (magrolimab) 是一种转移的头部和部状细胞癌.这就是Pembrolizumab.津巴布韦的房地产是什么

更多相关视频

Analysis of Human T Cell Activity in an Allogeneic Co-Culture Setting of Pre-Treated Tumor Cells

Analysis of Human T Cell Activity in an Allogeneic Co-Culture Setting of Pre-Treated Tumor Cells

Published on: March 7, 2025

Potentiation of Anticancer Antibody Efficacy by Antineoplastic Drugs: Detection of Antibody-drug Synergism Using the Combination Index Equation

Potentiation of Anticancer Antibody Efficacy by Antineoplastic Drugs: Detection of Antibody-drug Synergism Using the Combination Index Equation

Published on: January 19, 2019

相关概念视频

Treatment Resistant Cancers

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...